Company Profile
Company Profile
| Trade name | Aetas Pharma Inc. |
|---|---|
| Head office | 1-7 Kanda Ogawamachi, Chiyoda-ku, Tokyo 101-0052 |
| Date of establishment | May 23, 2000 |
| Paid-in capital | 97.13 million yen |
| Management Members | President and Representative Director |
| Main Business | Research and development and licensing of pharmaceutical products |
Characteristics of our company
1. We are an academia-initiated bio-venture aiming to develop drugs for unmet medical needs.
2. We are researching and developing novel therapeutic agents for heart and kidney diseases, both of which are increasing in terms of the number of patients in an ageing society.
3. The Company is developing ryanodine receptor 2 inhibitors, K201 and M201-A.
Company History
| 2000/05 | Aetas Inc. was established in Yotsuya, Shinjuku-ku, Tokyo, for the research and development of pharmaceutical products and management of patents. |
|---|---|
| 2004/10 | Company name changed to Aetas Pharma Inc. |
| 2008–2011 | Conducted Phase II clinical trials for intravenous K201 and Phase I and preliminary Phase II clinical trials for oral K201 in the U.S. and EU |
| 2009 | Synthesis of M201 compound and the initiation of efficacy and pharmacological studies |
| 2010 | Initiation of the development and screening of AK compounds |
| 2013/12 | M201 was accepted by A-STEP (JST, now AMED) as a ‘Proposal Title: Atrial Fibrillation and Flutter Drug’. |
| 2016 | Completed GLP non-clinical study of M201-A. |
| 2017 | Phase I clinical trial of M201-A was conducted and completed. |
| 2017/07 | Phase II clinical trial of M201-A injection in the early phase was adopted by AMED. |
| 2018/09 | ‘Development of Innovative Atrial Fibrillation Treatment with M201-A Hydrochloride’ was adopted by AMED |
| 2019/05 | Single-dose, early Phase II clinical trial (investigator-initiated) of M201-A hydrochloride injection in patients with paroxysmal atrial fibrillation was initiated. |
| 2020 | Conducted Phase I clinical trials (repeated-dose study) of M201-A |
| 2022/06 | Establishment of the Utsunomiya Office |
| 2023/11 | Commencement of Phase II study of M201-A injection for patients with heart failure and renal dysfunction |